共 24 条
Utilization of Stable Isotope Labeling to Facilitate the Identification of Polar Metabolites of KAF156, an Antimalarial Agent
被引:7
作者:
Huskey, Su-Er W.
[1
]
Forseth, Ry R.
[1
]
Li, Hongmei
[1
]
Jian, Zhigang
[1
]
Catoire, Alexandre
[1
]
Zhang, Jin
[1
]
Ray, Tapan
[1
]
He, Handan
[1
]
Flarakos, Jimmy
[1
]
Mangold, James B.
[1
]
机构:
[1] Novartis Inst BioMed Res, Drug Metab & Pharmacokinet, E Hanover, NJ USA
关键词:
TANDEM MASS-SPECTROMETRY;
ARTEMISININ RESISTANCE;
LIQUID-CHROMATOGRAPHY;
MALARIA VACCINE;
DRUG DISCOVERY;
PROPHYLAXIS;
EPHEDRINES;
SEPARATION;
SAFETY;
PHASE;
D O I:
10.1124/dmd.116.072108
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Identification of polar metabolites of drug candidates during development is often challenging. Several prominent polar metabolites of 2-amino-1-(2-(4-fluorophenyl)-3-((4-fluorophenyl) amino)-8,8-dimethyl-5,6- dihydroimidazo[1,2-a] pyrazin-7(8H)-yl) ethanone ([C-14] KAF156), an antimalarial agent, were detected in rat urine from an absorption, distribution, metabolism, and excretion study but could not be characterized by liquid chromatography-tandem mass spectrometry (LC-MS/MS) because of low ionization efficiency. In such instances, a strategy often chosen by investigators is to use a radiolabeled compound with high specific activity, having an isotopic mass ratio (i.e., [C-12]/[C-14]) and mass difference that serve as the basis for a mass filter using accurate mass spectrometry. Unfortunately, [C-14] KAF156-1 was uniformly labeled (n = 1-6) with the mass ratio of similar to 0.1. This ratio was insufficient to be useful as a mass filter despite the high specific activity (120 mu Ci/mg). At this stage in development, stable isotope labeled [C-13(6)] KAF156-1 was available as the internal standard for the quantification of KAF156. We were thus able to design an oral dose as a mixture of [C-14] KAF156-1 (specific activity 3.65 mu Ci/mg) and [C-13(6)] KAF156-1 with a mass ratio of [C-12]/[C-13(6)] as 0.9 and the mass difference as 6.0202. By using this mass filter strategy, four polar metabolites were successfully identified in rat urine. Subsequently, using a similar dual labeling approach, [C-14] KAF156-2 and [C-13(2)] KAF156-2 were synthesized to allow the detection of any putative polar metabolites that may have lost labeling during biotransformations using the previous [C-14] KAF156-1. Three polar metabolites were thereby identified and M43, a less polar metabolite, was proposed as the key intermediate metabolite leading to the formation of a total of seven polar metabolites. Overall this dual labeling approach proved practical and valuable for the identification of polar metabolites by LC-MS/MS.
引用
收藏
页码:1697 / 1708
页数:12
相关论文